Sophia Genetics/$SOPH
1D1W1MYTD1Y5YMAX
Capital at risk
About Sophia Genetics
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
- Ticker
- $SOPH
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 415
- Headquarters
- Rolle, Switzerland
- Website
- www.sophiagenetics.com
Sophia Genetics Metrics
BasicAdvanced
$710M
-
-$1.16
0.98
-
Price and volume
Market cap
$710M
Beta
0.98
52-week high
$8.98
52-week low
$3.41
Average daily volume
645K
Financial strength
Current ratio
2.688
Quick ratio
2.384
Long term debt to equity
0.711
Total debt to equity
0.744
Interest coverage (TTM)
-11.13%
Profitability
EBITDA (TTM)
-71.746
Gross margin (TTM)
66.63%
Net profit margin (TTM)
-93.86%
Operating margin (TTM)
-85.58%
Effective tax rate (TTM)
-0.72%
Revenue per employee (TTM)
$210,000
Management effectiveness
Return on assets (TTM)
-24.52%
Return on equity (TTM)
-101.22%
Valuation
Price to revenue (TTM)
6.749
Price to book
8.54
Price to tangible book (TTM)
15.12
Price to free cash flow (TTM)
-11.525
Free cash flow yield (TTM)
-8.68%
Free cash flow per share (TTM)
-0.724
Growth
Revenue change (TTM)
23.65%
Earnings per share change (TTM)
5.84%
3-year revenue growth (CAGR)
16.82%
3-year earnings per share growth (CAGR)
-1.65%
What the Analysts think about Sophia Genetics
Analyst ratings (Buy, Hold, Sell) for Sophia Genetics stock.
Analyst projections of the future price of Sophia Genetics stock.
Bulls say / Bears say
Sophia Genetics grew Q2 2026 revenue to $23.3 million, a 27% increase year-over-year, demonstrating accelerating top-line momentum. (PRNewswire)
U.S. revenue surged 64% year-over-year in Q2 2026, with analysis volume up 60%, underscoring strong penetration of the U.S. market. (PRNewswire)
Net dollar retention reached 117% in Q2 2026, up from 107% a year earlier, reflecting effective upselling and high platform stickiness. (PRNewswire)
Reported gross margin compressed to 64.6% in Q2 2026 from 67.0% a year ago, indicating potential pressure from higher compute or service delivery costs. (PRNewswire)
IFRS net loss remained at $22.4 million in Q2 2026, unchanged year-over-year, signaling persistent unprofitability at the bottom line. (PRNewswire)
The Q2 oversubscribed public offering raised $57.5 million, bringing cash to $107.7 million, but guided adjusted EBITDA losses of $29 million–$32 million in 2026 imply potential need for further fundraising to finance growth initiatives. (PRNewswire)
Data summarised monthly by Lightyear AI. Last updated on 7 Sept 2026.
Sophia Genetics Financial Performance
Revenues and expenses
Sophia Genetics Earnings Performance
Company profitability
Upcoming events
No upcoming events
Sophia Genetics News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.